

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 207/34, A61K 31/40	A1	(11) International Publication Number: WO 97/03958 (43) International Publication Date: 6 February 1997 (06.02.97)
(21) International Application Number: PCT/US96/11367 (22) International Filing Date: 8 July 1996 (08.07.96) (30) Priority Data: 60/001,454 17 July 1995 (17.07.95) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): MCKENZIE, Ann, T. [US/US]; 1932 Happy Hollow Road, West Lafayette, IN 47906 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		(81) Designated States: AU, BG, BR, CA, CN, CZ, EE, GE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, UZ, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: FORM III CRYSTALLINE (R-(R*,R*)-2-(4-FLUOROPHENYL)-BETA-DELTA-DIHYDROXY-5-(1-METHYL-ETHYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-1H-PYRROLE-1-HEPTANOIC ACID HEMI CALCIUM SALT (ATORVASTATIN) (57) Abstract A novel crystalline form of [R-(R*,R*)]-2-(4-fluorophenyl)- β,δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form III is characterized by its X-ray powder diffraction and/or solid state NMR is described, as well as methods for the preparation and pharmaceutical composition of the same, which is useful as an agent for treating hyperlipidemia and hypercholesterolemia.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

5

BACKGROUND OF THE INVENTION

25

30

35

-2-

[R-(R*,R*)]-2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid.

United States Patent Numbers 5,003,080; 5,097,045;
5,103,024; 5,124,482; 5,149,837; 5,155,251; 5,216,174;
5,245,047; 5,248,793; 5,280,126; 5,397,792; and
5,342,952, which are herein incorporated by reference,
disclose various processes and key intermediates for
preparing atorvastatin.

Atorvastatin is prepared as its calcium salt,
i.e., [R-(R*,R*)]-2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1). The
calcium salt is desirable since it enables atorvastatin
to be conveniently formulated in, for example, tablets,
capsules, lozenges, powders, and the like for oral
administration. Additionally, there is a need to
produce atorvastatin in a pure and crystalline form to
enable formulations to meet exacting pharmaceutical
requirements and specifications.

Furthermore, the process by which atorvastatin is
produced needs to be one which is amenable to large-
scale production. Additionally, it is desirable that
the product should be in a form that is readily
filterable and easily dried. Finally, it is
economically desirable that the product be stable for
extended periods of time without the need for
specialized storage conditions.

The processes in the above United States Patents
disclose amorphous atorvastatin which has unsuitable
filtration and drying characteristics for large-scale
production and must be protected from heat, light,
oxygen, and moisture.

We have now surprisingly and unexpectedly found
that atorvastatin can be prepared in crystalline form.
Thus, the present invention provides atorvastatin in a

-3-

new crystalline form designated Form III. Form III atorvastatin has different physical characteristics compared to the previous amorphous product.

5

SUMMARY OF THE INVENTION

10

Accordingly, the present invention is directed to crystalline Form III atorvastatin and hydrates thereof characterized by the following X-ray powder diffraction pattern expressed in terms of the 2θ , d-spacings, and relative intensities with a relative intensity of >25% measured on a Siemens D-500 diffractometer with $\text{CuK}\alpha$ radiation:

15

- 4 -

	2 θ	d	Relative Intensity (>25%)
	4.123	21.4140	49.20
	4.993	17.6832	30.82
	5.768	15.3099	28.69
5	7.670	11.5173	25.49
	8.451	10.4538	100.00
	15.962	5.5478	32.59
	16.619	5.3298	62.34
	17.731	4.9981	49.29
10	18.267	4.8526	45.12
	18.870	4.6989	39.52
	19.480	4.5531	36.59
	19.984	4.4393	70.34
	20.294	4.3722	69.54
15	21.105	4.2061	37.39
	21.670	4.0976	36.50
	23.318	3.8117	38.63
	24.405	3.6442	65.54
	24.967	3.5635	27.20
20	25.397	3.5041	33.75

Further, the present invention is directed to crystalline Form III atorvastatin and hydrates thereof characterized by the following solid-state ^{13}C nuclear magnetic resonance spectrum wherein chemical shift is expressed in parts per million measured on a Bruker AX-250 spectrometer:

-5-

Assignment		Chemical Shift
Spinning Side Band		214.8
		209.3
		202.3
5	C12 or C25	184.9
	C12 or C25	166.7
	C16	161.0(weak, broad)
Aromatic Carbons		
	C2-C5, C13-C18, C19-C24, C27-C32	140.1
10		135.2
		131.8
		128.9
		124.3
		122.2
15		117.2
		114.9
	C8, C10	69.8
		67.3
		65.6
20	Methylene Carbons	
	C6, C7, C9, C11	44.1
		40.4
		35.4
	C33	27.0
25		24.1
	C34	22.1
		19.9

30 As an inhibitor of HMG-CoA, the novel crystalline form of atorvastatin is useful as a hypolipidemic and hypocholesterolemic agent.

A still further embodiment of the present invention is a pharmaceutical composition for

-6-

administering an effective amount of crystalline
Form III atorvastatin in unit dosage form in the
treatment methods mentioned above. Finally, the
present invention is directed to methods for production
5 of Form III atorvastatin.

BRIEF DESCRIPTION OF THE DRAWINGS

10 The invention is further described by the
following nonlimiting examples which refer to the
accompanying Figures 1 to 2, short particulars of which
are given below.

15 Figure 1

Diffractogram of Form III atorvastatin (Y-axis = 0
to maximum intensity of 2815 counts per seconds (cps)).

Figure 2

20 Solid-state ^{13}C nuclear magnetic resonance
spectrum with spinning side bands identified by an
asterisk of Form III atorvastatin.

25 DETAILED DESCRIPTION OF THE INVENTION

Crystalline Form III atorvastatin may be
characterized by its X-ray powder diffraction pattern
and/or by its solid state nuclear magnetic resonance
30 spectra (NMR).

-7-

X-RAY POWDER DIFFRACTION

Form III Atorvastatin

5 Form III atorvastatin was characterized by its X-ray powder diffraction pattern. Thus, the X-ray diffraction pattern of Form III atorvastatin was measured on a Siemens D-500 diffractometer with CuK_α radiation.

10 Equipment

Siemens D-500 Diffractometer-Kristalloflex with an IBM-compatible interface, software = DIFFRAC AT (SOCABIM 1986, 1992).

15 CuK_α radiation (20 mA, 40 kV, $\lambda = 1.5406 \text{ \AA}$) Slits I and II at 1°) electronically filtered by the Kevex Psi Peltier Cooled Silicon [Si(Li)] Detector (Slits: III at 1° and IV at 0.15°).

Methodology

20 The silicon standard is run each day to check the X-ray tube alignment.

Continuous $\theta/2\theta$ coupled scan: 4.00° to 40.00° in 2θ , scan rate of $6^\circ/\text{min}$: 0.4 sec/ 0.04° step.

25 Sample tapped out of vial and pressed onto zero-background quartz in Al holder. Sample width 13-15 mm.

Samples are stored and run at room temperature.

30 Table 1 lists the 2θ , d-spacings, and relative intensities of all lines in the unground sample with a relative intensity of $>25\%$ for crystalline Form III atorvastatin. It should also be noted that the computer-generated unrounded numbers are listed in this table.

35

-8-

TABLE 1. Intensities and Peak Locations of All Diffraction Lines With Relative Intensity Greater Than 25% for Form III Atorvastatin

	2 θ	d	Relative Intensity (>25%)
5	4.123	21.4140	49.20
	4.993	17.6832	30.82
	5.768	15.3099	28.69
	7.670	11.5173	25.49
10	8.451	10.4538	100.00
	15.962	5.5478	32.59
	16.619	5.3298	62.34
	17.731	4.9981	49.29
	18.267	4.8526	45.12
15	18.870	4.6989	39.52
	19.480	4.5531	36.59
	19.984	4.4393	70.34
	20.294	4.3722	69.54
	21.105	4.2061	37.39
20	21.670	4.0976	36.50
	23.318	3.8117	38.63
	24.405	3.6442	65.54
	24.967	3.5635	27.20
	25.397	3.5041	33.75

SOLID STATE NUCLEAR MAGNETIC RESONANCE (NMR)


Methodology

30 All solid-state ^{13}C NMR measurements were made with a Bruker AX-250, 250 MHz NMR spectrometer. High resolution spectra were obtained using high-power proton decoupling and cross-polarization (CP) with magic-angle spinning (MAS) at approximately 5 kHz. The
35 magic-angle was adjusted using the Br signal of KBr by

-9-

detecting the side bands as described by Frye and Maciel (Frye J.S. and Maciel G.E., J. Mag. Res., 1982;48:125). Approximately 300 to 450 mg of sample packed into a canister-design rotor was used for each experiment. Chemical shifts were referenced to external tetrakis (trimethylsilyl)silane (methyl signal at 3.50 ppm) (Muntean J.V. and Stock L.M., J. Mag. Res., 1988;76:54).

Table 2 shows the solid-state NMR spectrum for crystalline Form III atorvastatin.



-10-

TABLE 2. Carbon Atom Assignment and Chemical Shift for Form III Atorvastatin

Assignment	Chemical Shift
Spinning Side Band	214.8
5	209.3
	202.3
C12 or C25	184.9
C12 or C25	166.7
C16	161.0 (weak, broad)
10	Aromatic Carbons
	C2-C5, C13-C18, C19-C24, C27-C32
	140.1
	135.2
	131.8
	128.9
15	124.3
	122.2
	117.2
	114.9
20	C8, C10
	69.8
	67.3
	65.6
	Methylene Carbons
	C6, C7, C9, C11
	44.1
	40.4
25	35.4
	C33
	27.0
	24.1
	C34
	22.1
	19.9
30	

Crystalline Form III atorvastatin of the present invention can exist in anhydrous form as well as hydrated forms. In general, the hydrated forms, are equivalent to unhydrated forms and are intended to be

-11-

encompassed within the scope of the present invention.

The present invention also provides a process for the preparation of crystalline Form III atorvastatin which comprises exposing atorvastatin to a high
5 relative humidity under conditions which yield crystalline Form III atorvastatin.

The precise conditions under which Form III of crystalline atorvastatin is formed may be empirically determined and it is only possible to give a method
10 which has been found to be suitable in practice.

Thus, for example, when the starting material is Form II of crystalline atorvastatin disclosed in concurrently filed United States Patent Application titled "Crystalline [R-(R*,R*)]-2-(4-fluorophenyl)- β , δ -
15 dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)" commonly owned, attorney's Case Number PD-5250-01-FJT, Serial Number _____ (Crystalline Form I and Form IV atorvastatin are also disclosed in this
20 application), the desired Form III of crystalline atorvastatin may be obtained by exposing the solid to a relative humidity of 95% for 11 days.

Crystalline Form II atorvastatin may be prepared from amorphous, a combination of amorphous and
25 crystalline Form I atorvastatin or crystalline Form I atorvastatin. Thus, for example, when the starting material is amorphous, a combination of amorphous and Form I, or crystalline Form I atorvastatin, the desired Form II of crystalline atorvastatin may be obtained by
30 suspending the solid in methanol containing about 40% to about 50% water until conversion to the required form is complete, followed by filtration.

Crystalline Form I atorvastatin may be prepared by crystallization under controlled conditions. In
35 particular, it can be prepared either from an aqueous solution of the corresponding basic salt such as, an

-12-

alkali metal salt, for example, lithium, potassium, sodium, and the like; ammonia or an amine salt; preferably, the sodium salt by addition of a calcium salt, such as, for example, calcium acetate and the like, or by suspending amorphous atorvastatin in water. In general, the use of a hydroxylic co-solvent such as, for example, a lower alkanol, for example methanol and the like, is preferred.

The compound of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compound of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compound of the present invention can be administered by inhalation, for example, intranasally. Additionally, the compound of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either compounds or a corresponding pharmaceutically acceptable salt of the compound of the present invention.

For preparing pharmaceutical compositions from the compound of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.

In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

-13-

In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

5 The powders and tablets preferably contain from two or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component, with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

10 For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

15 Liquid form preparations include solutions, suspensions, retention enemas, and emulsions, for example water or water propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

20 Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired.

-14-

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents..

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 0.5 mg to 100 mg, preferably 2.5 mg to 80 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents.

In therapeutic use as a hypolipidemic and/or hypocholesterolemic agent, crystalline Form III atorvastatin utilized in the pharmaceutical method of this invention is administered at the initial dosage of about 2.5 mg to about 80 mg daily. A daily dose range

-15-

of about 2.5 mg to about 20 mg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstance is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

The following nonlimiting examples illustrate the inventors' preferred methods for preparing the compounds of the invention.

EXAMPLE 1

[R-(R*,R*)]-2-(4-Fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (Form I Atorvastatin)

A mixture of (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide (atorvastatin lactone) (United States Patent Number 5,273,995) (75 kg), methyl tertiary-butyl ether (MTBE) (308 kg), methanol (190 L) is reacted with an aqueous solution of sodium hydroxide (5.72 kg in 950 L) at 48-58°C for 40 to 60 minutes to form the ring-opened sodium salt. After cooling to 25-35°C, the organic layer is discarded, and the aqueous layer is again extracted with MTBE (230 kg). The organic layer is discarded, and the MTBE saturated aqueous solution of the sodium salt is heated to 47-52°C. To this solution is added a solution of calcium acetate hemihydrate

-16-

(11.94 kg) dissolved in water (410 L), over at least 30 minutes. The mixture is seeded with a slurry of crystalline Form I atorvastatin (1.1 kg in 11 L water and 5 L methanol) shortly after addition of the calcium acetate solution. The mixture is then heated to 51-57°C for at least 10 minutes and then cooled to 15-40°C. The mixture is filtered, washed with a solution of water (300 L) and methanol (150 L) followed by water (450 L). The solid is dried at 60-70°C under vacuum for 3 to 4 days to give crystalline Form I atorvastatin (72.2 kg).

EXAMPLE 2

[R-(R*,R*)]-2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (Form II Atorvastatin)

A mixture of amorphous and crystalline Form I atorvastatin (100 g) was suspended in a mixture of methanol (1200 mL) and water (800 mL) and stirred for 3 days. The material was filtered, dried at 70°C under reduced pressure to give crystalline Form II atorvastatin.

EXAMPLE 3

[R-(R*,R*)]-2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (Form III Atorvastatin)

Form II atorvastatin (Example 2) is rotapped through a 50 mesh screen onto a 100 mesh screen and exposed in a humidity jar to 95% relative humidity for 11 days to afford crystalline Form III atorvastatin.

-17-

CLAIMS

1. Crystalline Form III atorvastatin and hydrates thereof characterized by the following X-ray powder diffraction pattern expressed in terms of the 2θ , d-spacings, and relative intensities with a relative intensity of >25% measured using $\text{CuK}\alpha$ radiation:

5

10

15

20

25

2θ	d	Relative Intensity (>25%)
4.123	21.4140	49.20
4.993	17.6832	30.82
5.768	15.3099	28.69
7.670	11.5173	25.49
8.451	10.4538	100.00
15.962	5.5478	32.59
16.619	5.3298	62.34
17.731	4.9981	49.29
18.267	4.8526	45.12
18.870	4.6989	39.52
19.480	4.5531	36.59
19.984	4.4393	70.34
20.294	4.3722	69.54
21.105	4.2061	37.39
21.670	4.0976	36.50
23.318	3.8117	38.63
24.405	3.6442	65.54
24.967	3.5635	27.20
25.397	3.5041	33.75

2. Crystalline Form III atorvastatin and hydrates thereof characterized by the following solid-state

-18-

¹³C nuclear magnetic resonance spectrum wherein
chemical shift is expressed in parts per million:


5	Assignment	Chemical Shift
	Spinning Side Band	214.8
		209.3
		202.3
	C12 or C25	184.9
10	C12 or C25	166.7
	C16	161.0 (weak, broad)
	Aromatic Carbons	
	C2-C5, C13-C18, C19-C24, C27-C32	140.1
		135.2
15		131.8
		128.9
		124.3
		122.2
		117.2
20		114.9
	C8, C10	69.8
		67.3
		65.6
	Methylene Carbons	
25	C6, C7, C9, C11	44.1
		40.4
		35.4
	C33	27.0
		24.1
30	C34	22.1
		19.9

-19-


3. A pharmaceutical composition in the form of tablets comprising crystalline Form III atorvastatin as defined in Claim 1 in admixture with at least one pharmaceutically acceptable excipient, diluent, or carrier.
5
4. A pharmaceutical composition in the form of capsules comprising crystalline Form III atorvastatin as defined in Claim 1 in admixture with at least one inert pharmaceutically acceptable excipient, diluent, or carrier.
5
5. A pharmaceutical composition in the form of a powder comprising crystalline Form III atorvastatin as defined in Claim 1 in admixture with at least one inert pharmaceutically acceptable excipient, diluent, or carrier.
5
6. A pharmaceutical composition in the form of lozenges comprising crystalline Form III atorvastatin as defined in Claim 1 in admixture with at least one inert pharmaceutically acceptable excipient, diluent, or carrier.
5
7. A pharmaceutical composition in the form of suppositories comprising crystalline Form III atorvastatin as defined in Claim 1 in admixture with at least one inert pharmaceutically acceptable excipient, diluent, or carrier.
5
8. A pharmaceutical composition in the form of retention enemas comprising crystalline Form III atorvastatin as defined in Claim 1 in admixture with at least one inert pharmaceutically acceptable excipient, diluent, or carrier.
5

-20-

9. A method of treating hyperlipidemia and hypercholesterolemia comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to Claim 1 in unit dosage form.
- 5



2/2



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 96/11367

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D207/34 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 16693 A (WARNER-LAMBERT CO., USA) 4 August 1994 see the whole document ---	1-9
A	US 5 316 765 A (FOLKERS, KARL A. ET AL) 31 May 1994 see the whole document ---	1-9
A	TETRAHEDRON LETT. (1992), 33(17), 2283-4 CODEN: TELEAY;ISSN: 0040-4039, 1992, XP000608147 BAUMANN, KELVIN L. ET AL: "The convergent synthesis of CI-981, an optically active, highly potent, tissue-selective inhibitor of HMG-CoA reductase" see the whole document --- -/--	1-9

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search

21 October 1996

Date of mailing of the international search report

25.10.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Kissler, B

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 96/11367

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EP 0 409 281 A (WARNER-LAMBERT CO., USA) 23 January 1991 see the whole document -----</p>	1-9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/11367

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 9 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inventor's International Application No
PCT/US 96/11367

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9416693	04-08-94	CA-A- 2150372 EP-A- 0680320 JP-T- 8505640	04-08-94 08-11-95 18-06-96
-----	-----	-----	-----
US-A-5316765	31-05-94	US-A- 5082650	21-01-92
-----	-----	-----	-----
EP-A-0409281	23-01-91	AU-B- 628198 AU-A- 5972490 CA-A- 2021546 FI-B- 94339 JP-A- 3058967 NO-B- 174709 NO-B- 176096 US-A- 5273995	10-09-92 24-01-91 22-01-91 15-05-95 14-03-91 14-03-94 24-10-94 28-12-93
-----	-----	-----	-----